{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 314,
  "pageCount": 415,
  "prevPage": 313,
  "nextPage": 315,
  "slideType": "testimonial",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a Q&A format to highlight expert opinion against the subject drug (DCCR/Vykat).",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/314",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-314",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.79
      },
      "kind": "callout",
      "text": "Initial evidence indicates PWS patients do better with GLP-1’s for both weight loss and hyperphagia",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ed4afba-8c63-47b9-a4bc-3512203b8df4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.48
      },
      "kind": "callout",
      "text": "Leading PWS authority more excited about potential of GLP’s; sees better results for hyperphagia + weight reduction",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b15ff7f3-d45d-40f4-afbb-16b461ece66a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "I think the GLP-1s, if I was going to bet, will probably be more effective than this drug from what I’ve seen about this drug so far, and the limited data I’ve got on the GLP-1s and the GLP-1s are likely to be cheaper",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b0-f09d9bbacbff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "A: “I think there are potentially other drugs that are going to be more effective. I think the GLP-1 drugs; I’ve begun to use that in a few people…I can imagine that, I think the GLP-1s, if I was going to bet, will probably be more effective than this drug from what I’ve seen about this drug so far, and the limited data I’ve got on the GLP-1s and the GLP-1s are likely to be cheaper”\nQ: “How many patients have you tried GLP-1s in?”\nA: “I’ve treated about 11 or 12.”\nQ: “It’s the same number. And you thought the effect was much better?”\nA: “Yes.”\nQ: “Is there even an anecdotal paper out there on GLP-1s in PWS? It seems like it would just be the obvious thing to try.\nA: “There’s a case report. There’s about six case reports from about two or three papers. . . I see reductions in hyperphagia, which are not dissimilar to that seen on average with DCCR. And I’m seeing weight loss in a way that wasn’t seen in the DCCR. And again, the small numbers.” - Trial investigator; endocrinologist; one of the most published authorities on PWS and hyperphagia",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad8a51b3-6768-4517-ac5e-290ca83c7965",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "“I suspect I’ll be using GLP-1s before I would be using this. From my experience with GLP-1’s to date, I’m quite hopeful…I had people who were weight stable and then lost weight when starting it or gaining weight, started it, and then leveled off. I’ve got HQ-CTs going back in time, and they were pretty constant. And then after starting, the HQ-CT came down. It could all be placebo. But I’ve got some estimate of the repeated measures. I’m more encouraged by that than by the DCCR.” -Trial investigator; endocrinologist; one of the most published authorities on PWS and hyperphagia",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6b70ee5-61a6-4497-bff5-e41507065204",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "He indicated treating about a dozen PWS patients with GLP-1’s and seeing reductions in hyperphagia and weight when he felt Vykat showed neither. Moreover, he tracked HQ-CT hyperphagia scores and thought the results were far more promising than Soleno’s – “the GLP-1’s, if I was going to bet, will probably be more effective than this drug…[from] the limited data I’ve got on belonid the GLP-1’s…I see reductions in hyperphagia…and I’m seeing weight loss in a way that wasn’t seen in the DCCR…I’ll be using GLP-1’s before I would be using this…from my experience with GLP-1’s to date, I’m quite hopeful…the HQ-CT score came down…I’m more encouraged by that than by the DCCR.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c70820a7-b886-46a5-8491-581a0fc328e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "I think the GLP-1s, if I was going to bet, will probably be more effective than this drug from what I’ve seen about this drug so far, and the limited data I’ve got on the GLP-1s and the GLP-1s are likely to be cheaper — Trial investigator; endocrinologist; one of the most published authorities on PWS and hyperphagia",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b0-f77463f94bb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88cef5b4-aa84-459a-b61c-3c6a7cd9cae9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #4 expressed enthusiasm about the potential of GLP-1’s in PWS patients, citing early data indicating they’re far more effective than Vykat and radically cheaper.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0348ab5-46bc-4b51-88a9-108d4b098a53",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}